Salix Pharmaceutics Ltd. (SLXP) tumbled 23% to $32.14 for the biggest retreat in the Russell 2000 Index. The drugmaker said the FDA wasn’t ready to approve at this time its Xifaxan drug for treating non-constipation irritable bowel syndrome without more information.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!